| AEs | Adverse events |
| AF | Annulus fibrosus |
| aRR | Adjusted Risk Ratio |
| BP | Biological Process |
| CC | Cellular Component |
| CEP | Cartilaginous endplate |
| CI | Confidence Interval |
| DMEM | Dulbecco’s Modified Eagle Medium |
| DPBS | Dulbecco’s phosphate-buffered saline |
| ECM | Extracellular matrix |
| EVs | Extracellular vesicles |
| GO | Gene Ontology |
| hPL | Human platelet lysate |
| MF | Molecular Function |
| MMPs | Matrix metalloproteinases |
| MSCs | Mesenchymal stem cells |
| NP | Nucleus pulposus |
| NTA | Nanoparticle tracking analysis |
| ODI | Oswestry Disability Index |
| Q1 | First Quartile |
| Q3 | Third Quartile |
| RNA | Ribonucleic acid |
| ROS | Reactive oxygen species |
| RR | Risk Ratio |
| SAE | Serious Adverse Event |
| SEC | Size exclusion chromatography |
| STROBE | Strengthening the Reporting of Observational Studies in Epidemiology |
| TFF | Tangential flow filtration |
| VAS | Visual Analog Scale |
| WJ-MSCs | Wharton’s jelly-derived mesenchymal stem cells |